ClinicalTrials.gg
Status unknownNCT01864902CART33Updated Jan 28, 2016

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

A Phase 1/2 interventional study of CART33 cells and anti-CD33 CART in Relapsed Adult Myeloid Leukemia and Chemotherapy Refractory Adult Myeloid Leukemia, sponsored by Chinese PLA General Hospital. Status unknown at 1 site in China. Open to participants aged 5 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-01-28.

Sponsored by Chinese PLA General Hospital · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Leukemia, Myeloid with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid · China.

Planned enrollment
13th of 14
10 · median 48
Started
2013
the only one that year
Phase 1/2
5 of 15
1 open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Chinese PLA General Hospital

Among the 15 studies in Leukemia, Myeloid with a site in China, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 1/2, and was the 2nd registered.

Leukemia, Myeloid

136 studies on the registry are indexed under Leukemia, Myeloid; 23 are open to participants now.

Browse Leukemia, Myeloid studies →

Open to participants now

4 of the 15 studies in Leukemia, Myeloid with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Leukemia, Myeloid studies recruiting now, 10 (53%) set no upper age limit and 7 (37%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 5 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Leukemia, Myeloid with a site in China, or all of them as a file.
02

Study summary

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.

PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD33 vector (referred to as CART-33 cells).

II. Determine duration of in vivo survival of CART-33 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-33 TCR zeta:CD137 and TCR (T-cell receptor) zeta cells over time.

SECONDARY OBJECTIVES:

I. For patients with detectable disease, measure anti-leukemia response due to CART-33 cell infusions.

II. To determine if the CD137 transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-33 TCR zeta:CD137 and TCR zeta cells over time.

III. Estimate relative trafficking of CART-33 cells in bone marrow.

IV. For patients with stored or accessible leukemia blasts, determine leukemia cell killing by CART-33 cells in vitro.

V. Determine if cellular or humoral host immunity develops against the murine anti-CD33, and assess correlation with loss of detectable CART-33 (loss of engraftment).

VI. Determine the relative subsets of CART-33 T cells (Tcm, Tem, and Treg).

OUTLINE: Patients are assigned to 1 group according to order of enrollment.

Patients receive anti-CD33-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells on days 0,1, and 2 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 13 years.

03

Conditions studied

  • Relapsed Adult Myeloid Leukemia
  • Chemotherapy Refractory Adult Myeloid Leukemia

Browse trials for

Keywords

  • CD33 positive acute myeloid leukemia (AML)
04

Who can participate

Ages eligible
5 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with CD33+ acute myeloid leukemia in patients with no available curative treatment options (such as or allogeneic SCT) who have limited prognosis (several months to \< 2 year survival) with currently available therapies will be enrolled

    • CD33+ acute myeloid leukemia CR can not be achieved after at least 2 prior combination chemotherapy regimens.

AML in CR(complete remission)2 or CR3 and not eligible for allogeneic SCT because of age, comorbid disease, or lack of available family member or unrelated donor.

Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).

after prior autologous or allogenic SCT. AML patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.

Residual disease after primary therapy and not eligible for autologous SCT

  • Expected survival > 12 weeks
  • Creatinine \< 2.5 mg/dl
  • (alanine aminotransferase)/AST (aspartate aminotransferase)\< 3x normal
  • \< 2.0 mg/dl
  • Any relapse after prior SCT will make patient eligible regardless of other prior therapy
  • Adequate venous access for apheresis, and no other for leukapheresis
  • Voluntary is given

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women

    • The safety of this therapy on unborn children is not known
    • Female study participants of must have a negative serum or urine pregnancy test performed within 48 hours before infusion
    • Uncontrolled active infection
    • Active or infection
    • Concurrent use of systemic . Recent or current use of inhaled steroids is not exclusionary
    • Previously treatment with any gene therapy products
    • Feasibility assessment during screening demonstrates \< 30% transduction of target lymphocytes, or insufficient expansion (\< 5-fold) in response to CD3/CD137 costimulation
    • Any uncontrolled active medical disorder that would preclude participation as outlined
    • infection
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    anti-CD33 CAR T cells

    Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.

    Biological: CART33 cells · Biological: anti-CD33 CART · Biological: anti-CD33 CAR T cells

Interventions

  • BiologicalCART33 cells

    genetically modified lymphocyte therapy

    Also known as: chimeric antigen receptor T cells with specificity for CD33

  • Biologicalanti-CD33 CART

    Also known as: CART33

  • Biologicalanti-CD33 CAR T cells

    Drug page: Anti-CD33 CAR T-cellsStudies of Anti-CD33 CAR T-cellsAnti-CD33 CAR T-cells pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

06

What researchers measure

Primary outcomes

  1. Occurrence of study related adverse events

    defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment

    Time frame: Until week 24

Secondary outcomes

  1. Anti-leukemia responses to CART-33 cell infusions

    Time frame: up to 24 weeks

Other outcomes

  1. in vivo existence of CART33

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Hematological Department, Affiliated Hospital of Changzhi Medical College
    Beijing, Beijing 100853, China
    Recruiting
    • Weidong Han, Dr. · Contacthanwdrsw@sina.com · 86-10-13651392893
    • Xuliang Shen, Dr. · Contactshenxlcyp@sohu.com · 86-355-13015365546
    • Ying Liu, Dr. · Sub investigator
    • Yao Wang, Dr. · Sub investigator
08

References and documents

Publications

  • Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, Wang LL, Han WD. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015 Jan;23(1):184-91. doi: 10.1038/mt.2014.164. Epub 2014 Sep 1. PubMed 25174587 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Apr 2016 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2013
First posted
May 30, 2013
Start
Apr 2013
Primary completionEst.
Apr 2016
CompletionEst.
Apr 2017
Last update
Jan 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01864902
Responsible party
Han weidong (PI, Chinese PLA General Hospital) — Principal investigator
First posted
May 30, 2013
Start date
Apr 2013
Primary completion
Apr 2016 (estimated)
Completion
Apr 2017 (estimated)
Last update
Jan 28, 2016

Study contacts

Weidong Han, Dr.
Contact
hanwdrsw@sina.com
86-10-13651392893
Xuliang Shen, Dr.
Contact
shenxlcyp@sohu.com
86-355-13015365546

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion